Endothelial dysfunction in (pre)diabetes: Characteristics, causative mechanisms and pathogenic role in type 2 diabetes

  • Etto C. Eringa
  • Erik H. Serne
  • Rick I. Meijer
  • Casper G. Schalkwijk
  • Alfons J. H. M. Houben
  • Coen D. A. Stehouwer
  • Yvo M. Smulders
  • Victor W. M. van Hinsbergh
Article

Abstract

Endothelial dysfunction associated with diabetes and cardiovascular disease is characterized by changes in vasoregulation, enhanced generation of reactive oxygen intermediates, inflammatory activation, and altered barrier function. These endothelial alterations contribute to excess cardiovascular disease in diabetes, but may also play a role in the pathogenesis of diabetes, especially type 2. The mechanisms underlying endothelial dysfunction in diabetes differ between type 1 (T1D) and type 2 diabetes (T2D): hyperglycemia contributes to endothelial dysfunction in all individuals with diabetes, whereas the causative mechanisms in T2D also include impaired insulin signaling in endothelial cells, dyslipidemia and altered secretion of bioactive substances (adipokines) by adipose tissue. The close association of so-called perivascular adipose tissue with arteries and arterioles facilitates the exposure of vascular endothelium to adipokines, particularly if inflammation activates the adipose tissue. Glucose and adipokines activate specific intracellular signaling pathways in endothelium, which in concert result in endothelial dysfunction in diabetes. Here, we review the characteristics of endothelial dysfunction in diabetes, the causative mechanisms involved and the role of endothelial dysfunction(s) in the pathogenesis of T2D. Finally, we will discuss the therapeutic potential of endothelial dysfunction in T2D.

Keywords

Diabetes Obesity Insulin Endothelium Intracellular signaling 

1 Introduction

Diabetes mellitus is a metabolic disease with a high and growing prevalence. Age-standardized prevalence is currently 9.2–9.8 % globally, with an estimated number of ~347 million patients [1]. Type 1 diabetes (T1D) is characterized by an absolute deficiency of insulin attributable to pancreatic insufficiency. Type 2 diabetes (T2D), which accounts for ~90 % of all cases of diabetes, is characterized by insulin resistance, i.e. impairment of insulin-induced whole-body glucose uptake, and a relative insulin deficiency in spite of high plasma levels of insulin [2]. Because of the progressive dysfunction of the pancreatic β-cells, this can eventually lead to an absolute deficiency of insulin for tissues in type 2 diabetes [2].

Endothelial dysfunction comprises a number of functional alterations in the vascular endothelium, such as impaired regulation of vasodilation and vasoconstriction, impaired or excessive angiogenesis, decreased barrier function and increased inflammatory activation, all of which are associated with cardiovascular disease. In T1D, endothelial dysfunction is predominantly triggered by the metabolic changes related to hyperglycemia. With age, a number of microvascular complications develop in T1D patients, in particular retinopathy, nephropathy, and impaired wound healing [3]. In T2D the relationship between endothelial dysfunction and diabetes is more complex, as endothelial dysfunction starts well before the onset of overt diabetes [4, 5, 6, 7]. Shared mechanisms may underlie endothelial dysfunction and the development of hyperglycemia in T2D, as factors such as dyslipidemia and inflammation of adipose tissue have been linked to both traits [8, 9]. Here, we will review specific aspects and causes of endothelial dysfunction in diabetes. Furthermore, we will discuss the contribution of endothelial dysfunction to the pathogenesis of T2D and its potential as a therapeutic target.

2 Defining diabetes-specific endothelial dysfunction

Endothelial dysfunction can be defined as impairment of one or more endothelial functions. In insulin resistance and diabetes, a variety of endothelial functions is compromised, including regulation of vascular tone [10, 11, 12, 13, 14, 15] and organ perfusion [16, 17], inhibition of inflammation [9], transendothelial transport of blood solutes [18], prevention of coagulation [19] and initiation of angiogenesis and arteriogenesis [20, 21]. In the present review, we will review the specific changes in endothelial function associated with insulin resistance and diabetes and the signaling pathways within endothelial cells that are involved in these alteration, and will discuss the potential of vascular endothelium as a target for prevention of diabetes (type 2) as well as complications of diabetes.

Three facets of the pathogenesis of diabetes can induce specific changes in endothelial signaling and function. These are impairment of insulin signaling, accumulation and inflammation of (ectopic) fat and hyperglycemia. These three factors all directly affect endothelial function, through impairment of insulin-stimulated vasodilatation and effects of adipokines on vascular endothelium and accumulation of glucose and glycated proteins in endothelial cells. We will discuss the relationship of these three facets of diabetes to altered endothelial properties.

3 Impairment of insulin signaling in vascular endothelium

Since the 1990s insulin has been known to have direct effects on vascular endothelium [22, 23], the best known of these effects being modulation of vascular tone [12, 23, 24, 25]. Insulin’s effects on vascular tone are predominantly mediated by the vascular endothelium and are effected by two different signaling pathways that control the release of nitric oxide (NO) [12, 23, 24, 26] and endothelin-1 (ET-1) [12, 27, 28] (Fig. 1). Under normal conditions, the net result of these two antagonistic effects of insulin is vasodilatation or a neutral effect [12, 15, 29]. Insulin-stimulated NO production is subsequent activation of the insulin receptor, insulin receptor substrate 1 (IRS1), phosphatidylinositol (3) kinase (PI3-kinase), phosphoinositide-dependent kinase 1 (PDK1), Akt/protein kinase B and endothelial nitric oxide synthase (eNOS; Fig. 1) [24, 30, 31]. Aside from IRS1, insulin receptor substrate 2 (IRS2) was recently reported to mediate insulin’s effects on vascular endothelium [32], but the relationship between IRS1 and IRS2 in this pathway is not clear. Although the signaling pathway involved in insulin-stimulated ET-1 production is not completely clear at present, it is critically dependent on activation of raf-1, MEK and ERK1/2 [27, 28, 33] (Fig. 2). The signaling events upstream of raf-1 resulting in insulin-mediated ET-1 production have not been identified yet.
Fig. 1

Regulation of insulin signaling in endothelial cells at multiple levels. IGF-1, insulin-like growth factor 1; FFA, Free fatty acids; TNFα, tumour necrosis factor alpha; IGFR, IGF-1 receptor; InsR, insulin receptor; IRS1/2; insulin receptor substrates 1 and 2; PKCθ, protein kinase C theta; p38 MAPK, p38 mitogen activated protein kinase; IKK, IkappaB kinase; JNK, c-jun N-terminal kinase; PI3K, phosphatidylinositol 3-kinase; AMPK, 5′AMP-activated protein kinase; MEK, MAPK/ERK kinase; Β-Ar2, beta arrestin 2; GRK2, G protein-coupled receptor kinase 2; ERK1/2, extracellular signal-regulated kinase 1/2; eNOS, endothelial NO synthase; ET-1, endothelin-1. for further details see text

Fig. 2

Roles of endothelial dysfunction in the pathogenesis of T2D. In the pancreas, insulin secretion is determined by angiogenesis during development, endothelial TGFβ release and by lipid accumulation in beta cells, which is controlled by VEGF-B induced transport of lipids across endothelium. In muscle interstitial insulin concentrations are determined by the endothelial surface area and the rate of transendothelial insulin transport. Insulin-mediated glucose uptake in muscle cells is decreased by intracellular lipid accumulation, which is controlled by VEGF-B stimulated lipid transport across endothelium. In liver, VEGF-B induced transendothelial lipid transport contributes to the formation of the fatty liver and liver insulin resistance. For further details see text

Vascular insulin resistance, i.e. resistance to insulin-mediated vasodilatation, is characteristic of insulin resistant humans [4, 16, 34] and has been demonstrated in animal models of obesity [15, 35, 36] and hypertension [28]. Insulin resistance and impaired insulin-mediated vasodilatation are associated with hypophosphorylation of Akt and eNOS [10], whereas insulin’s vasoconstrictor effects are intact in insulin resistance [15, 36, 37, 38]. Altered signaling by the insulin receptor substrates is critical to this impairment. Downregulation of IRS-1 and IRS-2 has been observed in insulin resistance [32, 36] and indeed, deletion of IRS-2 in vascular endothelium results in vascular dysfunction [32]. IRS1-deficient mice have been reported to show impaired endothelium-dependent vasodilatation [39, 40]. Furthermore, we have observed impaired insulin-stimulated activation of eNOS in femoral arteries of IRS1−/− mice (W Bakker, E Eringa et al., unpublished data).

3.1 Intracellular control of endothelial insulin signaling

A number of intracellular mechanisms have been identified that inhibit insulin signaling in vascular endothelium. Inhibition of insulin signaling in endothelial cells can occur at the level of the insulin receptor and the insulin receptor substrates or downstream of the insulin receptor signaling proteins, at the level of Akt, eNOS or through NO scavenging by reactive oxygen species. At the level of the insulin receptor, the receptor for insulin-like growth factor 1 (IGF-1) has been shown to form hybrid receptors with the insulin receptor with a reduced activity [36, 41, 42]. At the level of the IRS proteins, several kinases have been shown to inhibit insulin signaling through phosphorylation of IRS1. They include c-jun N-terminal kinase (JNK) [43], the protein kinase C isoform theta (PKCθ) [44, 45, 46], p38 mitogen-activated kinase (p38 MAPK) [47], and IκB kinase (IKK)[48]. These kinases target specific serine residues at IRS1, such as Ser 307 (JNK) [43, 49] and Ser 504, 532 [45] and 1101 (PKCθ) [46].

The PKC isoform PKCβ has previously been linked to vascular dysfunction in diabetes [50], and inhibition of PKCβ was recently reported to improve insulin signaling in man [51]. In T2D, inhibition of PKCβ was shown to enhance insulin-stimulated eNOS phosphorylation at Ser 1177, which showed a positive correlation with flow-mediated vasodilatation [51]. Interestingly, basal phosphorylation of eNOS was increased in diabetic patients, and this was also reversed after PKCβ inhibition [51]. In another recent study on interaction between PKCβ and insulin in the vessel wall, PKCβ was found to decrease insulin-stimulated eNOS activity by controlling the localization of Akt and eNOS. This change in Akt localization is dependent on inhibition of β-arrestin 2 by G Protein–Coupled Receptor Kinase 2 (GRK2).

Although less intensely investigated, insulin’s vasoconstrictor effects are also regulated by specific intracellular signaling cascades. The multi-domain adaptor protein APPL1 has been shown to inhibit insulin-stimulated ET-1 synthesis by decreasing the phosphorylation of raf-1, which mediates insulin-induced activation of ERK1/2 and ET-1 release from endothelial cells [33]. APPL1 overexpression was also found to restore insulin-mediated vasoreactivity in high fat diet-induced obese mice [33]. In recent research on muscle resistance arteries using the AMPK agonists AICAR and globular adiponectin, we have found that AMPK activation enhances insulin-mediated vasodilatation by inhibiting insulin-mediated activation of ERK1/2 (MP de Boer and EC Eringa, unpublished data). These studies show that regulation of insulin signaling in endothelial cells occurs at multiple levels of signaling from the insulin receptor to eNOS and ERK1/2 (see Fig. 1 for an overview of regulation of insulin signaling in endothelial cells). The balance between the activities of these regulatory pathways ultimately determines the effects of insulin on vascular endothelium.

4 (Perivascular) Adipose tissue control of endothelial signaling and function

Adipose tissue, especially in the abdomen (intra-abdominal adipose tissue, AAT) and around blood vessels (perivascular adipose tissue, PVAT) [52] has been shown to control insulin sensitivity [53], endothelial function [54], especially insulin-mediated vasoreactivity [35, 43, 44, 55, 56]. Adipose tissue secretes a wide variety of bioactive substances (adipokines) that act directly on vascular endothelium [57], and the list is still growing [58]. Examples of adipokines relevant to endothelial (dys)function are adiponectin [59, 60, 61], leptin [62], fatty acids [5, 44, 48] and reactive oxygen species [63, 64, 65, 66].

With regard to endothelial function, PVAT is increasingly recognized as a critical fat depot that regulates local vascular tone [61] and inflammation [67, 68]. We and others have shown that PVAT stimulates endothelium-dependent vasodilatation, and that this function of PVAT is impaired in obesity and T2D [61, 69, 70]. PVAT consists of adipocytes, fibroblasts, stem cells [71], inflammatory cells [72, 73] and nerves [72]. In obesity PVAT expands, in parallel to growth of intra-abdominal adipose tissue [74, 75]. The mechanisms involved in the expansion of perivascular adipose tissue involve differentiation of resident mesenchymal stem cells/preadipocytes as well as infiltration and differentiation of stem cells from bone marrow. The conversion of stem cells/preadipocytes to adipocytes can be triggered by activation of PPARγ [76], and can be inhibited by the Wnt signaling pathway and preadipocyte factor 1 (pref-1) [77].

In obesity and atherosclerosis, infiltration of PVAT by immune cells such as macrophages and T lymphocytes has been shown in the aorta [78, 79, 80], and this inflammation is a critical determinant of vasodilator properties of PVAT [61, 69, 70]. Accumulation of T lymphocytes may trigger expansion of perivascular adipose tissue as T cells stimulate adipogenesis by production of the natural PPARγ activator 15d-PGJ2 [79]. In addition to T lymphocytes, mast cells have also been shown to control adipose tissue expansion and insulin sensitivity [81]. The pro-adipogenic effect of mast cells may also be mediated by PPARγ, as mast cells secrete 15d-PGJ2 [82]. Macrophages do not affect the quantity of PAT, but produce cytokines that alter the secretion of adipokines by PVAT [69]. Interestingly, endothelium-specific inhibition of NFκB signaling improves muscle blood flow, insulin sensitivity and life span in mice [83], further substantiating the role of inflammation in the control of muscle perfusion and insulin sensitivity.

We have recently shown that PVAT controls insulin-stimulated vasodilation in muscle resistance arteries through two antagonistic signaling pathways: a vasodilator pathway mediated by adiponectin and 5′AMP-activated protein kinase (AMPK) and an inflammatory pathway mediated by c-jun N-terminal kinase (JNK) [70]. Remarkably, acute inhibition of JNK activity using a cell-permeable peptide fully restored insulin-mediated vasodilatation in the presence of PVAT of type 2 diabetic db/db mice. This indicates that inflammation of PVAT is an important step in determining endothelium-dependent vasodilatation in obesity and T2D.

It should be noted that adipose tissue inflammation may not only contribute to endothelial dysfunction, but hypoperfusion of adipose tissue and the resulting hypoxia may also trigger inflammation and alter adipokine secretion [61, 84, 85]. Indeed, impaired perfusion of adipose tissue is statistically related to insulin resistance in man [86]. As such, adipose tissue inflammation and endothelial dysfunction may form a positive feedback loop in obesity-related insulin resistance.

5 Exercise-like signaling in vascular endothelium: 5′AMP-activated protein kinase

Aside from its role in PVAT signaling, the “exercise kinase” AMPK [87] can be activated by a variety of stimuli including metformin [88] and shear stress [89], and has been shown to control several endothelial functions. These include NO-dependent vasodilatation and muscle perfusion [90, 91], angiogenesis [92] and inflammation [93]. AMPK regulates eNOS activity by phosphorylation at two serine residues, Ser 633 [94] and Ser 1177 [90, 95], and by stimulating the association of eNOS with heat-shock protein 90 [88]. Mice deficient in one of the kinase subunits of AMPK, AMPKα2, display enhanced vascular inflammation and accelerated atherosclerosis [89]. Moreover, the AMPK agonist and exercise mimetic 5-Aminoimidazole-4-Carboxamide 1-β-D-Ribofuranoside (AICAR) [87], enhances NO production, perfusion [90, 96] and insulin sensitivity [97] in muscle. To what extent the microvascular effects of AICAR contribute to its metabolic effects remains to be assessed. In conclusion, AMPK carries significant potential as a part of exercise-mimicking therapies, but its role in the pathogenesis of endothelial dysfunction in human diabetes has not been fully elucidated.

6 Effects of hyperglycemia and advanced glycation endproducts on endothelial function

Hyperglycemia is a well-known cause of endothelial dysfunction in diabetes, and overproduction of reactive oxygen species (ROS) is critical to effects of hyperglycemia on vascular endothelium [98, 99]. For an overview of hyperglycemia-induced endothelial dysfunction, the reader is referred to an excellent review by Giacco and Brownlee [3]. Earlier, Michael Brownlee brought several pathways that were activated by hyperglycemia together in one mechanism, in which enhanced generation of superoxide causes sequentially PARP activation, inhibition of GAPDH and accumulation of glycolysis intermediates. In the rodents subsequent studies showed that interference of superoxide generation or reduction of these glycolysis intermediates by activation of the pentose phosphate shunt improved endothelial microvasular function [100, 101]. One of the major mechanisms underlying hyperglycemia-induced endothelial dysfunction is formation of advanced glycation endproducts (AGEs), which have been demonstrated to trigger proinflammatory changes and decrease NO activity through peroxynitrite formation from NO and ROS [98]. Aside from formation of AGEs in the circulation, intracellular accumulation of the AGE intermediate methylglyoxal (MGO) is critical to impairment of endothelium-dependent vasorelaxation by hyperglycemia [102]. Overexpression of glyoxalase-1 (GLO-1), the enzyme that degrades MGO, rescued relaxation to acetylcholine in diabetic rats [99, 103] and prevented vascular degeneration in the retina [104].

7 Roles of endothelial dysfunction in the pathogenesis of type 2 diabetes

Aside from its role in cardiovascular complications in diabetes, altered functioning of vascular endothelium has been implicated in a number of aspects of the pathogenesis of diabetes. These include insulin resistance, lipotoxicity, and impaired insulin secretion.

7.1 Endothelial insulin signaling, insulin transport across vascular endothelium and insulin resistance

Insulin action in endothelial cells is thought to determine the net transport of insulin from the blood across vascular endothelium to the muscle interstitium and ultimately, the myocytes [105, 106]. Proof for this concept has been obtained in a series of elegant studies by the groups of Barrett, Clark and Bergman [107, 108, 109]. Two endothelial effects of insulin are relevant to this process: regulation of the endothelial surface area and transendothelial insulin transport [106].

In spite of the demonstration that insulin access to myocytes determines insulin sensitivity, the quantitative contribution of these effects of insulin to insulin resistance has been uncertain until recently. Therefore, several models of impaired endothelial insulin signaling have been used: mice lacking insulin receptors in vascular endothelium and mice lacking IRS1 and/or IRS2 in vascular endothelium. Surprisingly, these models have yielded somewhat divergent results regarding insulin sensitivity. Vascular endothelium-specific insulin receptor knockout (VENIRKO) mice as well as mice with expressing a dominant-negative mutant insulin receptor (ESMIRO mice) are not insulin resistant [110, 111], despite a 30–60 % decrease in eNOS expression. In contrast, endothelium-specific deletion of IRS2 in endothelium results in a ~50 % decrease in insulin sensitivity [32]. Interestingly, endothelium-specific deletion of IRS1 did not decrease insulin sensitivity in that study. A satisfactory explanation for the discrepancy between the effects of endothelium-specific deletion of the insulin receptor and IRS2 on insulin sensitivity is not yet available, but two things should be considered. First, IRS proteins are activated by factors other than insulin, such as IGF1 [112] and leptin [113]. Therefore, the physiological effects of IRS deletion may be stronger than that of IR deletion. Second, deletion of the insulin receptor in vascular endothelium not only reduces expression of eNOS, but also reduces expression of the potent vasoconstrictor ET-1 by ~40 % [110]. Therefore, a decrease in insulin sensitivity resulting from impaired eNOS activity [114] may be masked by impairment of insulin’s vasoconstrictor effects in endothelium-specific IR knockout mice. In support, ET-1 has been shown to reduce insulin sensitivity in man [115] and reducing ET-1 activity increases insulin sensitivity in obese subjects [116, 117].

7.2 Endothelial lipid transport as a determinant of lipotoxicity-induced insulin resistance and type 2 diabetes

Accumulation of lipid in skeletal muscle, the myocardium and the liver are important causes of impaired insulin-stimulated glucose uptake in these tissues [118]. Two recent studies have demonstrated that vascular endothelial growth factor B (VEGF-B) and regulation of lipid transport across vascular endothelium are critical determinants of lipid accumulation in muscle, heart and even liver, a tissue with a relatively permeable endothelial barrier [119, 120]. Moreover, inhibiting VEGF-B expression was sufficient to prevent T2D, restore insulin sensitivity and preserve beta cell morphology in db/db mice and mice fed a high-fat diet. These fascinating data show that lipid transport across vascular endothelium determines susceptibility to ectopic lipid accumulation and the associated progression of T2D.

7.3 Endothelial dysfunction as a determinant of insulin secretion

A relative insufficiency of pancreatic insulin secretion is the hallmark of T2D [2]. It has long been assumed that insulin secretion by the pancreas was only determined by metabolic regulation of the beta cells. Nevertheless, vascular endothelium has recently been shown to play an important additional regulatory role in pancreatic insulin secretion. First, decreased islet vascularization was shown to precede reduced insulin secretion by the pancreas in a rat model of T2D [121]. Second, in the studies on VEGF-B controlled lipid transport across vascular endothelium mentioned above, inhibition of VEGF-B by a monoclonal antibody increased insulin secretion in the pancreas by limiting lipid accumulation in beta cells [120]. Finally, expression of the glycoprotein thrombospondin-1 by endothelial cells in the pancreas is necessary for normal glucose-stimulated insulin secretion [122]. This regulatory role of thrombospondin-1 is mediated by transforming growth factor beta (TGFβ), as overexpression of TGFβ restored insulin secretion in TSP-1−/− deficient mice. Taken together, these data suggest that the vascular endothelium regulates insulin secretion by controlling lipid access to beta cells, maintaining adequate blood supply and stimulating local TGFβ activity. The contribution of these processes to insulin secretion in man has yet to be determined.

8 Impaired endothelial insulin signaling and atherosclerosis

Impairment of intracellular insulin signaling is a hallmark of insulin resistance and T2D, and is associated with accelerated atherosclerosis. Downregulation of IRS-1 and IRS-2, critical mediators of insulin signaling in endothelium [31, 32] has been observed in insulin resistance [32, 36]. In genome-wide association studies genetic variation in the IRS1 promoter has been linked to both T2D and risk of early myocardial infarction [123, 124, 125], suggesting a causal link between insulin signaling defects and cardiovascular disease. To provide a mechanistic explanation for this association, a recent study in ApoE−/− mice, a mouse model of atherosclerosis, showed that genetic deletion of insulin receptors in vascular endothelium induced a >2-fold increase in atherosclerotic lesion size. This effect of vascular insulin resistance was associated with reduced Ser 1177 phosphorylation of eNOS and enhanced vascular inflammation. Taken together, these data strongly suggest that impairment of vascular effects of insulin is a useful target for prevention of cardiovascular complications in T2D.

9 The vascular endothelium as a therapeutic target in diabetes

At present, therapeutic strategies used in the management of T1D aim to control blood glucose levels, in order to prevent diabetes complications [126]. In T2D, treatment targets are prevention diabetes as well as its cardiovascular complications. Metformin, life style intervention [127] and bariatric surgery [128] have been applied successfully in diabetes prevention, but are less than optimal in preventing its cardiovascular complications [129], and the worldwide prevalence of T2D is still rising [1]. Moreover, insulin resistance is widespread in Western countries, especially in obesity [130]. Therefore, there is a continuing need for effective preventive strategies for T2D and its complications. Aside from lowering risk of cardiovascular complications in diabetes, improving endothelium-dependent NO production and protecting the endothelial barrier carry significant promise as a target for preventing diabetes and its cardiovascular complications. Improving muscle perfusion may enhance delivery of insulin, glucose and insulin-sensitizing drugs to myocytes, thus increasing insulin sensitivity. A number of treatments have been developed for this purpose (Table 1), and we will discuss a few examples.
Table 1

Effects of interventions in endothelium-dependent signaling and their effect on insulin sensitivity and fasting glucose. PDE5, phosphodiesterase 5; ETR, endothelin receptor

Intervention

Insulin sensitivity

Fasting glucose

Applied in humans

Reference

PDE5 inhibition

 

[131, 134]

Nitrate Supplementation

 

[132]

ETR blockade

ND

[116, 117]

eNOS overexpression

=

 

[133]

VEGF-B inhibition

 

[120]

Increasing NO bioactivity can be achieved by inhibiting phosphodiesterase 5 (PDE5-) activity [131], increasing dietary intake of nitrate [132] or overexpression of eNOS [133]. As a proof of concept, the PDE5 inhibitor sildenafil has been shown to improve insulin sensitivity in diet-induced insulin-resistant mice [131, 134]. Dietary supplementation of nitrate can also increase NO bioavailability, and has been found to improve insulin sensitivity in eNOS-deficient mice [132]. Interesting, overexpression of eNOS in mice potently induced weight loss, but did not improve insulin sensitivity and even increased fasting glucose [133].

Decreasing ET-1 activity using endothelin receptor blockers (ETRBs) has been shown to improve endothelium-dependent vasodilatation, muscle blood flow and insulin sensitivity in human insulin resistance and T2D [115, 117].

Exercise, one of the best known and effective strategies for preventing T2D and cardiovascular disease [135], also antagonizes ET-1-induced decreases in leg blood flow, providing a physiological way to decrease endothelin activity [136, 137]. As mentioned above, effects of exercise may be mimicked by AMPK agonists such as AICAR.

Vascular insulin signaling can be improved using inhibitors of protein kinase C (PKC), such as ruboxistaurin [51]. Especially PKCβ has emerged as a promising target, and PKC inhibition has been shown in multiple studies in mice and humans to improve endothelial insulin signaling, nitric oxide synthesis and barrier function in diabetes [51, 138, 139]. In addition, PKCθ has been shown to impair endothelial insulin signaling and may be an additionally relevant PKC isoform for improving endothelial function [44, 46], but evidence in humans has yet to be obtained.

As argued above, inhibiting endothelial lipid transport is a promising goal for diabetes prevention and management. The beneficial effect of VEGF-B inhibition on lipid accumulation in muscle, liver and the pancreas has been described in mice, and awaits proof-of-concept studies in man. These data further support the potential of improving endothelial barrier function for treating T2D and it cardiovascular complications.

Finally, while cardiovascular disease and diabetes are consensus clinical end points, strategies aimed at increasing insulin resistance should be carefully designed. Insulin resistance is a common occurrence in the general population and in patients and may be beneficial in conditions of metabolic stress such as fasting, growth and trauma [140]. Therefore, the chance of harmful side effects of increasing insulin sensitivity should be considered when devising new therapies for diabetes prevention.

In conclusion, altered functioning of the vascular endothelium, characterized by altered regulation of vascular tone and tissue perfusion, altered barrier function and increased activity of inflammatory signaling, is a highly relevant mechanism linking the pathogeneses of diabetes and cardiovascular disease. Obesity, insulin resistance and diabetes are characterized by specific impairments in endothelial cell signaling and function, which provide promising targets for prevention of both diabetes and its cardiovascular complications.

Notes

Acknowledgements

ECE is sponsored by the Netherlands Organization for Scientific Research (Grant 916.76.179) and EHS is supported by the Netherlands Heart Foundation (Grant 2009B098).

References

  1. 1.
    Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.PubMedCrossRefGoogle Scholar
  2. 2.
    DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.PubMedCrossRefGoogle Scholar
  3. 3.
    Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.PubMedCrossRefGoogle Scholar
  4. 4.
    de Jongh RT, Serne EH, IJzerman RG, De Vries G, Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation. 2004;109:2529–35.PubMedCrossRefGoogle Scholar
  5. 5.
    de Jongh RT, Serne EH, IJzerman RG, de Vries G, Stehouwer CDA. Free fatty acid levels modulate microvascular function: Relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes. 2004;53:2873–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000;101:1780–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48:1856–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365:1817–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Okon EB, Chung AWY, Rauniyar P, et al. Compromised arterial function in human type 2 diabetic patients. Diabetes. 2005;54:2415–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106:1783–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation. 1999;100:820–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Van den Heuvel M, Sorop O, Koopmans SJ, et al. Coronary microvascular dysfunction in a porcine model of early atherosclerosis and diabetes. Am J Physiol Heart Circ Physiol. 2012;302:H85–94.PubMedCrossRefGoogle Scholar
  14. 14.
    Roos MH, Eringa EC, van Rodijnen WF, van Lambalgen TA, ter Wee PM, Tangelder GJ. Preglomerular and postglomerular basal diameter changes and reactivity to angiotensin II in obese rats. Diabetes Obes Metab. 2008;10:898–905.PubMedCrossRefGoogle Scholar
  15. 15.
    Eringa EC, Stehouwer CDA, Roos MH, Westerhof N, Sipkema P. Selective resistance to vasoactive effects of insulin in muscle resistance arteries of obese Zucker (fa/fa) rats. Am J Physiol Endocrinol Metab. 2007;293:E1134–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Meijer RI, de Boer MP, Groen MR et al. (2012) Insulin-induced microvascular recruitment in skin and muscle are related and both are associated with whole body glucose uptake. MicrocirculationGoogle Scholar
  17. 17.
    Kostromina E, Gustavsson N, Wang X, et al. Glucose intolerance and impaired insulin secretion in pancreas-specific signal transducer and activator of transcription-3 knockout mice are associated with microvascular alterations in the pancreas. Endocrinology. 2010;151:2050–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Rensing KL, von der Thusen JH, Weijers EM, et al. Endothelial insulin receptor expression in human atherosclerotic plaques: linking micro- and macrovascular disease in diabetes? Atherosclerosis. 2012;222:208–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes. 2006;55:1133–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res. 2007;101:948–56.PubMedCrossRefGoogle Scholar
  21. 21.
    Prakash R, Somanath PR, El-Remessy AB, et al. Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2 diabetes involves VEGF and peroxynitrite signaling. Diabetes. 2012;61:1533–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest. 1990;85:1844–52.PubMedCrossRefGoogle Scholar
  23. 23.
    Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 1996;98:894–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Eringa EC, Stehouwer CD, Merlijn T, Westerhof N, Sipkema P. Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc Res. 2002;56:464–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 1995;96:786–92.PubMedCrossRefGoogle Scholar
  26. 26.
    Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt- dependent phosphorylation. Nature. 1999;399:601–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Eringa EC, Stehouwer CDA, Nieuw Amerongen GP, Ouwehand L, Westerhof N, Sipkema P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am J Physiol Heart Circ Physiol. 2004;287:H2043–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Potenza MA, Marasciulo FL, Chieppa DM, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol. 2005;289:H813–22.PubMedCrossRefGoogle Scholar
  29. 29.
    de Jongh RT, Clark AD, IJzerman RG, Serne EH, De Vries G, Stehouwer CD (2004) Physiological hyperinsulinaemia increases intramuscular microvascular reactive hyperaemia and vasomotion in healthy volunteers. DiabetologiaGoogle Scholar
  30. 30.
    Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539–45.PubMedCrossRefGoogle Scholar
  31. 31.
    Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol. 2002;16:1931–42.PubMedCrossRefGoogle Scholar
  32. 32.
    Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metabolism. 2011;13:294–307.PubMedCrossRefGoogle Scholar
  33. 33.
    Wang Y, Cheng KK, Lam KS, et al. APPL1 counteracts obesity-induced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice. Diabetes. 2011;60:3044–54.PubMedCrossRefGoogle Scholar
  34. 34.
    Clerk LH, Vincent MA, Lindner JR, Clark MG, Rattigan S, Barrett EJ. The vasodilatory actions of insulin on resistance and terminal arterioles and their impact on muscle glucose uptake. Diabetes Metab Res Rev. 2004;20:3–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Kim F, Pham M, Maloney E, et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol. 2008;28:1982–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Jiang ZY, Lin YW, Clemont A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999;104:447–57.PubMedCrossRefGoogle Scholar
  37. 37.
    Gudbjornsdottir S, Elam M, Sellgren J, Anderson EA. Insulin increases forearm vascular resistance in obese, insulin-resistant hypertensives. J Hypertens. 1996;14:91–7.PubMedGoogle Scholar
  38. 38.
    Ferri C, Carlomagno A, Coassin S, et al. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men. Diabetes Care. 1995;18:226–33.PubMedCrossRefGoogle Scholar
  39. 39.
    Kubota T, Kubota N, Moroi M, et al. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation. 2003;107:3073.PubMedCrossRefGoogle Scholar
  40. 40.
    Abe H, Yamada N, Kamata K, et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest. 1998;101:1784–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Abbas A, Imrie H, Viswambharan H, et al. The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes. 2011;60:2169–78.PubMedCrossRefGoogle Scholar
  42. 42.
    Li G, Barrett EJ, Wang H, Chai W, Liu Z. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology. 2005;146:4690–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Eringa EC, Stehouwer CDA, Walburg K, et al. Physiological concentrations of insulin induce endothelin-dependent vasoconstriction of skeletal muscle resistance arteries in the presence of tumor necrosis factor-alpha: Dependence on c-Jun N-terminal kinase. Arterioscler Thromb Vasc Biol. 2006;26:274–80.PubMedCrossRefGoogle Scholar
  44. 44.
    Bakker W, Sipkema P, Stehouwer CDA, et al. Protein kinase C theta activation induces insulin-mediated constriction of muscle resistance arteries. Diabetes. 2008;57:706–13.PubMedCrossRefGoogle Scholar
  45. 45.
    Wang C, Liu M, Riojas RA, et al. Protein kinase C theta (PKC{theta})-dependent phosphorylation of PDK1 at Ser504 and Ser532 contributes to palmitate-induced insulin resistance. J Biol Chem. 2009;284:2038–44.PubMedCrossRefGoogle Scholar
  46. 46.
    Li Y, Soos TJ, Li X, et al. Protein kinase C theta inhibits insulin signaling by phosphorylating IRS1 at Ser1101. J Biol Chem. 2004;279:45304–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology. 2007;148:3356–63.PubMedCrossRefGoogle Scholar
  48. 48.
    Kim F, Tysseling KA, Rice J, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKK{beta}. Arterioscler Thromb Vasc Biol. 2005;25:989–94.PubMedCrossRefGoogle Scholar
  49. 49.
    Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002;277:1531–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996;272:728–31.PubMedCrossRefGoogle Scholar
  51. 51.
    Tabit CE, Shenouda SM, Holbrook M et al (2012) Protein kinase-C beta contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. CirculationGoogle Scholar
  52. 52.
    Meijer R, Serne E, Smulders Y, van Hinsbergh V, Yudkin J, Eringa E (2011) Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease. Current Diabetes Reports 1-7Google Scholar
  53. 53.
    Rytka JM, Wueest S, Schoenle EJ, Konrad D. The portal theory supported by Venous DrainageΓÇôSelective fat transplantation. Diabetes. 2011;60:56–63.PubMedCrossRefGoogle Scholar
  54. 54.
    Hagita S, Osaka M, Shimokado K, Yoshida M. Adipose inflammation initiates recruitment of leukocytes to mouse femoral artery: role of adipo-vascular axis in chronic inflammation. PLoS One. 2011;6:e19871.PubMedCrossRefGoogle Scholar
  55. 55.
    Meijer RI, Bakker W, Alta CAF, et al. Perivascular adipose tissue control of insulin-induced vasoreactivity in muscle is impaired in db/db mice. Diabetes. 2013;62:590–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Rask-Madsen C, Dominguez H, Ihlemann N, Hermann T, Kober L, Torp-Pedersen C. Tumor necrosis factor-{alpha} inhibits insulin’s stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation. 2003;108:1815–21.PubMedCrossRefGoogle Scholar
  57. 57.
    Houben AJ, Eringa EC, Jonk AM, Serne EH, Smulders YM, Stehouwer CD. Perivascular fat and the microcirculation: relevance to insulin resistance, diabetes, and cardiovascular disease. Curr Cardiovasc Risk Rep. 2012;6:80–90.PubMedCrossRefGoogle Scholar
  58. 58.
    Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.PubMedCrossRefGoogle Scholar
  59. 59.
    Wong WT, Tian XY, Xu A, et al. Adiponectin is required for PPARgamma-mediated improvement of endothelial function in diabetic mice. Cell Metab. 2011;14:104–15.PubMedCrossRefGoogle Scholar
  60. 60.
    Ingelsson E, Arnlov J, Zethelius B, et al. Associations of serum adiponectin with skeletal muscle morphology and insulin sensitivity. J Clin Endocrinol Metab. 2009;94:953–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Greenstein AS, Khavandi K, Withers SB, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation. 2009;119:1661–70.PubMedCrossRefGoogle Scholar
  62. 62.
    Vecchione C, Aretini A, Maffei A, et al. Cooperation between insulin and leptin in the modulation of vascular tone. Hypertension. 2003;42:166–70.PubMedCrossRefGoogle Scholar
  63. 63.
    Xu X, Yavar Z, Verdin M, et al. Effect of early particulate air pollution exposure on obesity in mice: Role of p47phox. Arterioscler Thromb Vasc Biol. 2010;30:2518–27.PubMedCrossRefGoogle Scholar
  64. 64.
    Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II − induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449–60.PubMedCrossRefGoogle Scholar
  65. 65.
    Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105:1656–62.PubMedCrossRefGoogle Scholar
  66. 66.
    Marchesi C, Ebrahimian T, Angulo O, Paradis P, Schiffrin EL. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension. 2009;54:1384–92.PubMedCrossRefGoogle Scholar
  67. 67.
    Chatterjee TK, Stoll LL, Denning GM, et al. Proinflammatory phenotype of perivascular adipocytes: Influence of high-fat feeding. Circ Res. 2009;104:541–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Henrichot E, Juge-Aubry CE, Pernin A, et al. Production of chemokines by perivascular adipose tissue: A role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol. 2005;25:2594–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Withers SB, gabiti-Rosei C, Livingstone DM, et al. Macrophage activation is responsible for loss of anticontractile function in inflamed perivascular fat. Arterioscler Thromb Vasc Biol. 2011;31:908–13.PubMedCrossRefGoogle Scholar
  70. 70.
    Meijer RI, Bakker W, Alta CAF et al. (2012) Perivascular adipose tissue control of insulin-induced vasoreactivity in muscle is impaired in db/db Mice. Diabetes (In press)Google Scholar
  71. 71.
    Hu Y, Zhang Z, Torsney E, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest. 2004;113:1258–65.PubMedGoogle Scholar
  72. 72.
    Thureson-Klein A, Stijarne L. Ultrastructural features of mast cells in human omental veins. Blood Vessels. 1979;16:311–9.PubMedGoogle Scholar
  73. 73.
    Takaoka M, Suzuki H, Shioda S, et al. Endovascular injury induces rapid phenotypic changes in perivascular adipose tissue. Arterioscler Thromb Vasc Biol. 2010;30:1576–82.PubMedCrossRefGoogle Scholar
  74. 74.
    Iacobellis G, Ribaudo MC, Assael F, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab. 2003;88:5163–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Rittig K, Staib K, Machann J et al. (2008) Perivascular fatty tissue at the brachial artery is linked to insulin resistance but not to local endothelial dysfunction. Diabetologia. %20Google Scholar
  76. 76.
    De Coppi P, Milan G, Scarda A, et al. Rosiglitazone modifies the adipogenic potential of human muscle satellite cells. Diabetologia. 2006;49:1962–73.PubMedCrossRefGoogle Scholar
  77. 77.
    Moon YS, Smas CM, Lee K, et al. Mice lacking paternally expressed Pref-1/Dlk1 display growth retardation and accelerated adiposity. Mol Cell Biol. 2002;22:5585–92.PubMedCrossRefGoogle Scholar
  78. 78.
    Police SB, Thatcher SE, Charnigo R, Daugherty A, Cassis LA. Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2009;29:1458–64.PubMedCrossRefGoogle Scholar
  79. 79.
    Feldon SE, O’Loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP. Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol. 2006;169:1183–93.PubMedCrossRefGoogle Scholar
  80. 80.
    Tsuruda T, Kato J, Hatakeyama K, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res. 2008;102:1368–77.PubMedCrossRefGoogle Scholar
  81. 81.
    Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med. 2009;15:940–5.PubMedCrossRefGoogle Scholar
  82. 82.
    Ito S, Narumiya S, Hayaishi O. Prostaglandin D2: a biochemical perspective. Prostaglandins Leukot. Essent. Fatty Acids. 1989;37:219–34.CrossRefGoogle Scholar
  83. 83.
    Hasegawa Y, Saito T, Ogihara T, et al. Blockade of the nuclear factor-kappaB pathway in the endothelium prevents insulin resistance and prolongs life span. Circulation. 2012;125:1122–33.PubMedCrossRefGoogle Scholar
  84. 84.
    Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007;56:901–11.PubMedCrossRefGoogle Scholar
  85. 85.
    Yin J, Gao Z, He Q, Zhou D, Guo Z, Ye J. Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. Am J Physiol Endocrinol Metab. 2009;296:E333–42.PubMedCrossRefGoogle Scholar
  86. 86.
    Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LKM, Frayn KN. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes. 2002;51:2467–73.PubMedCrossRefGoogle Scholar
  87. 87.
    Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134:405–15.PubMedCrossRefGoogle Scholar
  88. 88.
    Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55:496–505.PubMedCrossRefGoogle Scholar
  89. 89.
    Young A, Wu W, Sun W, et al. Flow activation of AMP-activated protein kinase in vascular endothelium leads to kruppel-like factor 2 expression. Arterioscler Thromb Vasc Biol. 2009;29:1902–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Eringa EC, Bradley EA, Stehouwer CDA, et al. Activation of AMP-activated protein kinase by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside in the muscle microcirculation increases nitric oxide synthesis and microvascular perfusion. Arterioscler Thromb Vasc Biol. 2010;30:1137–42.PubMedCrossRefGoogle Scholar
  91. 91.
    Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem. 2003;278:31629–39.PubMedCrossRefGoogle Scholar
  92. 92.
    Ouchi N, Kobayashi H, Kihara S, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem. 2004;279:1304–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Dong Y, Zhang M, Liang B, et al. Reduction of AMP-activated protein kinase {alpha}2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation. 2010;121:792–803.PubMedCrossRefGoogle Scholar
  94. 94.
    Chen Z, Peng IC, Sun W, et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res. 2009;104:496–505.PubMedCrossRefGoogle Scholar
  95. 95.
    Chen Z, Mitchelhill KI, Michell BJ, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999;443:285–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Bosselaar M, Boon H, van Loon LJC, van den Broek PHH, Smits P, Tack CJ. Intra-arterial AICA-riboside administration induces NO-dependent vasodilation in vivo in human skeletal muscle. Am J Physiol Endocrinol Metab. 2009;297:E759–66.PubMedCrossRefGoogle Scholar
  97. 97.
    Cuthbertson DJ, Babraj JA, Mustard KJW, et al. 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes. 2007;56:2078–84.PubMedCrossRefGoogle Scholar
  98. 98.
    Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 2005;54:1615–25.PubMedCrossRefGoogle Scholar
  99. 99.
    Brouwers O, Niessen PM, Haenen G, et al. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia. 2010;53:989–1000.PubMedCrossRefGoogle Scholar
  100. 100.
    Ceradini DJ, Yao D, Grogan RH, et al. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem. 2008;283:10930–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9:294–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Shinohara M, Thornalley PJ, Giardino I, et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest. 1998;101:1142–7.PubMedCrossRefGoogle Scholar
  103. 103.
    Brouwers O, Niessen PM, Ferreira I, et al. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem. 2011;286:1374–80.PubMedCrossRefGoogle Scholar
  104. 104.
    Berner AK, Brouwers O, Pringle R, et al. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia. 2012;55:845–54.PubMedCrossRefGoogle Scholar
  105. 105.
    Wang H, Wang AX, Liu Z, Barrett EJ. Insulin signaling stimulates insulin transport by bovine aortic endothelial cells. Diabetes. 2008;57:540–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Barrett EJ, Eggleston EM, Inyard AC, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia. 2009;52:752–64.PubMedCrossRefGoogle Scholar
  107. 107.
    Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006;55:1436–42.PubMedCrossRefGoogle Scholar
  108. 108.
    Kolka CM, Harrison LN, Lottati M, Chiu JD, Kirkman EL, Bergman RN. Diet-induced obesity prevents interstitial dispersion of insulin in skeletal muscle. Diabetes. 2010;59:619–26.PubMedCrossRefGoogle Scholar
  109. 109.
    Chiu JD, Richey JM, Harrison LN, et al. Direct administration of insulin into skeletal muscle reveals that the transport of insulin across the capillary endothelium limits the time course of insulin to activate glucose disposal. Diabetes. 2008;57:828–35.PubMedCrossRefGoogle Scholar
  110. 110.
    Vicent D, Ilany J, Kondo T, et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest. 2003;111:1373–80.PubMedGoogle Scholar
  111. 111.
    Duncan ER, Crossey PA, Walker S, et al. Effect of endothelium-specific insulin resistance on endothelial function in vivo. Diabetes. 2008;57:3307–14.PubMedCrossRefGoogle Scholar
  112. 112.
    Araki E, Lipes MA, Patti ME, et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature. 1994;372:186–90.PubMedCrossRefGoogle Scholar
  113. 113.
    Kellerer M, Koch M, Metzinger E, Mushack J, Capp E, Haring H. Leptin activates PI-3 kinase in C2C12 myotubes via janus kinase-2 (JAK-2) and insulin receptor substrate-2 (IRS-2) dependent pathways. Diabetologia. 1997;40:1358–62.PubMedCrossRefGoogle Scholar
  114. 114.
    Shankar RR, Wu Y, Shen H-Q, Zhu J-S, Baron AD (2000) Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49Google Scholar
  115. 115.
    Shemyakin A, Salehzadeh F, Esteves Duque-Guimaraes D, et al. Endothelin-1 reduces glucose uptake in human skeletal muscle in vivo and in vitro. Diabetes. 2011;60:2061–7.PubMedCrossRefGoogle Scholar
  116. 116.
    Ahlborg G, Shemyakin A, Bohm F, Gonon A, Pernow J. Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care. 2007;30:591–6.PubMedCrossRefGoogle Scholar
  117. 117.
    Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes. 2007;56:728–34.PubMedCrossRefGoogle Scholar
  118. 118.
    Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-[beta] and NF-[kappa]B. Nat Med. 2005;11:183–90.PubMedCrossRefGoogle Scholar
  119. 119.
    Hagberg CE, Falkevall A, Wang X, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature. 2010;464:917–21.PubMedCrossRefGoogle Scholar
  120. 120.
    Hagberg CE, Mehlem A, Falkevall A, et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature. 2012;490:426–30.PubMedCrossRefGoogle Scholar
  121. 121.
    Giroix MH, Irminger JC, Lacraz G, et al. Hypercholesterolaemia, signs of islet microangiopathy and altered angiogenesis precede onset of type 2 diabetes in the Goto-Kakizaki (GK) rat. Diabetologia. 2011;54:2451–62.PubMedCrossRefGoogle Scholar
  122. 122.
    Olerud J, Mokhtari D, Johansson M, et al. Thrombospondin-1: an islet endothelial cell signal of importance for beta-cell function. Diabetes. 2011;60:1946–54.PubMedCrossRefGoogle Scholar
  123. 123.
    Kilpelainen TO, Zillikens MC, Stancakova A et al. (2011) Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat. GenetGoogle Scholar
  124. 124.
    Rung J, Cauchi S, Albrechtsen A, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet. 2009;41:1110–5.PubMedCrossRefGoogle Scholar
  125. 125.
    Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443–53.PubMedCrossRefGoogle Scholar
  126. 126.
    de Boer I, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366–76Google Scholar
  127. 127.
    Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRefGoogle Scholar
  128. 128.
    Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.PubMedCrossRefGoogle Scholar
  129. 129.
    Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.PubMedCrossRefGoogle Scholar
  130. 130.
    Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG. Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care. 2006;29:2427–32.PubMedCrossRefGoogle Scholar
  131. 131.
    Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes. 2007;56:1025–33.PubMedCrossRefGoogle Scholar
  132. 132.
    Carlstrom M, Larsen FJ, Nystrom T, et al. Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice. PNAS. 2010;107:17716–20.PubMedCrossRefGoogle Scholar
  133. 133.
    Sansbury BE, Cummins TD, Tang Y et al. (2012) Overexpression of endothelial nitric oxide synthase prevents diet-induced obesity and regulates adipocyte phenotype. Circulation ResearchGoogle Scholar
  134. 134.
    Kang L, Ayala JE, Lee-Young RS, et al. Diet-induced muscle insulin resistance is associated with extracellular matrix remodeling and interaction with integrin α2β1 in mice. Diabetes. 2011;60:416–26.PubMedCrossRefGoogle Scholar
  135. 135.
    Coker RH, Williams RH, Yeo SE, et al. The impact of exercise training compared to caloric restriction on hepatic and peripheral insulin resistance in obesity. Endocr Rev. 2009;30:745–a.Google Scholar
  136. 136.
    Wray DW, Nishiyama SK, Donato AJ, Sander M, Wagner PD, Richardson RS. Endothelin-1-mediated vasoconstriction at rest and during dynamic exercise in healthy humans. Am J Physiol Heart Circ Physiol. 2007;293:H2550–6.PubMedCrossRefGoogle Scholar
  137. 137.
    Fujita S, Rasmussen BB, Cadenas JG, et al. Aerobic exercise overcomes the age-related insulin resistance of muscle protein metabolism by improving endothelial function and Akt/Mammalian target of rapamycin signaling. Diabetes. 2007;56:1615–22.PubMedCrossRefGoogle Scholar
  138. 138.
    Booth G, Stalker TJ, Lefer AM, Scalia R. Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes. 2002;51:1556–64.PubMedCrossRefGoogle Scholar
  139. 139.
    Murakami T, Frey T, Lin C, Antonetti DA. Protein kinase cbeta phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes. 2012;61:1573–83.PubMedCrossRefGoogle Scholar
  140. 140.
    Soeters MR, Soeters PB. The evolutionary benefit of insulin resistance. Clin Nutr. 2012;31:1002–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Etto C. Eringa
    • 1
    • 4
  • Erik H. Serne
    • 2
  • Rick I. Meijer
    • 2
  • Casper G. Schalkwijk
    • 3
  • Alfons J. H. M. Houben
    • 3
  • Coen D. A. Stehouwer
    • 3
  • Yvo M. Smulders
    • 2
  • Victor W. M. van Hinsbergh
    • 1
  1. 1.Departments of PhysiologyVU University Medical CenterAmsterdamthe Netherlands
  2. 2.Departments of Internal MedicineVU University Medical CenterAmsterdamthe Netherlands
  3. 3.Department of Internal MedicineMaastricht University Medical CentreMaastrichtThe Netherlands
  4. 4.Laboratory for PhysiologyAmsterdamThe Netherlands

Personalised recommendations